Pubblicazioni relative alla Tecnologia Amyposomes®  e AmypoPharma R&D:

  1. Mancini S, Balducci C, Micotti E, Tolomeo D, Forloni G, Masserini M, Re F.
    Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease.
    J Control Release. 2017 May 10. pii: S0168-3659(17)30588-6. doi: 10.1016/j.jconrel.2017.05.013.

               
  2. Balducci, Mancini, Minniti, La Vitola, Zotti, Sancini, Mauri , Cagnotto, Colombo, Fiordaliso, Grigoli, Salmona, Snellman, Haaparanta-Solin, Forloni, Masserini, Re.
    Multifunctional Liposomes Reduce Brain β-Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models.
    J.Neurosci. 2014 Oct 15;34(42):14022-31. doi: 10.1523/JNEUROSCI.0284-14.2014.
        
  3. Conti E, Gregori M, Radice I, Da Re F, Grana D, Re F, Salvati E, Masserini M, Ferrarese C, Zoia CP, Tremolizzo L

    Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease.

    Neurochem Int. 2017 Feb 24. pii: S0197-0186(16)30345-X.          
                 

  4. Rokka J, Snellman A, Kaasalainen M, Salonen J, Zona C, La Ferla B, Nicotra F, Re F, Masserini M, Forsback S, Lopez-Picon F, Rinne JO, Haaparanta-Solin M, Solin O

    (18)F-labeling syntheses and preclinical evaluation offunctionalized nanoliposomes for Alzheimer's disease.

    Eur J Pharm Sci. 2016 Jun 10;88:257-66.       
                        

  5. Mancini S, Minniti S, Gregori M, Sancini G, Cagnotto A, Couraud PO, Ordóñez-Gutiérrez L, Wandosell F, Salmona M, Re F
    The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer'sdisease
    Nanomedicine. 2016 Jan;12(1):43-52.
                   
  6. Bana L, Minniti S, Salvati E, Sesana S, Zambelli V, Cagnotto A, Orlando A, Cazzaniga E, ZwartR,Scheper W, Masserini M, Re F.
    Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease
    Nanomedicine. 2014 Oct;10(7):1583-90.

  7. F. Re , I. Cambianica , C. Zona, S. Sesana, R. Rigolio, F. Nicotra, G.Forloni, A. Cagnotto, M. Salmona, M. Masserini, G. Sancini
    Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model
    Nanomedicine: Nanotechnology, Biology, and Medicine- Vol.7 (2011) 551–559

  8. Ordóñez-GutiérrezL, Re F, Bereczki E, Ioja E, Gregori M, Andersen AJ, Antón M, Moghimi SM, Pei JJ, Masserini M, WandosellF.
    Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-β levels in APP/PS1 transgenic mice 
    Nanomedicine. 2015 Feb;11(2):421-30.

  9. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M, Couraud PO, Moghimi SM, Masserini M, Sancini G.
    Functionalization with ApoE-derived peptide senhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide
    J Biotechnol. 2011 Dic;156(4):341-6. Epub 2011 Jul 6 doi: 10.1016/j.nano.2014.09.015.

  10. Marco Gobbi, Francesca Re, Mara Canovi, MartenBeeg, Maria Gregori, Silvia Sesana, Sandro Sonnino, Doriano Brogioli, Claudia Musicanti, Paolo Gasco, Mario Salmona, Massimo Masserini
    Lipid-based nanoparticles with high bindingaffinity for amyloid-β1-42 peptide
    Biomaterials, Sept. 2010, Vol. 31 - Pages 6519-6529

Altre pubblicazioni al seguente link: http://www.nadproject.eu/index.php?option=com_content&view=article&id=45&Itemid=68WW